SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

12 Feb 2024 Evaluate
The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 0.21 millions was observed as compared to Rs. 0.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -16.34 millions as compared to Net Loss of Rs. -7.06 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 further decreased to -21.96% as compared to -6.95% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 0.21 0.00 0.00 0.21 0.00 0.00 0.00 39.39 0.00
Other Income -9.01 0.00 0.00 -7.87 0.00 0.00 0.00 0.15 0.00
PBIDT -21.96 -6.95 215.97 -47.10 -12.86 266.25 -98.87 1.52 -6604.61
Interest 0.00 0.00 0.00 0.01 0.03 -66.67 0.05 0.03 66.67
PBDT -21.96 -6.95 215.97 -47.11 -12.89 265.48 -98.92 1.49 -6738.93
Depreciation 0.14 0.08 75.00 0.31 0.14 121.43 0.17 0.09 88.89
PBT -22.10 -7.03 214.37 -47.42 -13.03 263.93 -99.09 1.40 -7177.86
TAX -5.76 0.03 -19300.00 -12.66 0.92 -1476.09 -23.52 -0.05 46940.00
Deferred Tax -5.76 0.03 -19300.00 -12.66 0.92 -1476.09 -23.52 -0.05 46940.00
PAT -16.34 -7.06 131.44 -34.76 -13.95 149.18 -75.57 1.45 -5311.72
Equity 214.44 130.86 63.87 214.86 130.86 64.19 214.44 102.69 108.82
PBIDTM(%) -10457.14 0.00 0.00 -22428.57 0.00 0.00 0.00 3.86 0.00

Pharmaids Pharma Share Price

32.42 1.50 (4.85%)
21-Apr-2026 09:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1242.75
Cipla 1230.00
Zydus Lifesciences 935.00
Lupin 2337.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×